POS-350. Finerenone in mild to severe chronic kidney disease and type 2 diabetes: The fidelity prespecified pooled analysis

Simple item page
dc.contributor.authorRossing, Peter
dc.contributor.authorAgarwal, Rajiv L.
dc.contributor.authorAnker, Stefan D.
dc.contributor.authorFilippatos, Gerasimos S.
dc.contributor.authorPitt, Bertram
dc.contributor.authorRuilope Urioste, Luis Miguel
dc.contributor.authorJoseph, Amer
dc.contributor.authorGebel, Martin
dc.contributor.authorKolkhof, Peter
dc.contributor.authorNowack, Christina
dc.contributor.authorBakris, George
dc.date.accessioned2022-04-30T14:51:24Z
dc.date.available2022-04-30T14:51:24Z
dc.date.issued2022
dc.description.abstractPatients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have a residual risk of CKD progression despite current therapies, which tends to worsen with more advanced CKD. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, decreased the risk of kidney and cardiovascular (CV) outcomes in phase III trials for patients with CKD and T2D. Combining finerenone with other CKD in T2D therapies, such as sodium-glucose co-transporter-2 inhibitors (SGLT-2is) is of interest, but more data are needed. FI nerenone in chronic kiD ney diseasE and type 2 diabetes: Combined FIDEL IO-DKD and FI GARO-DKD T rial programme analY sis (FIDELITY) aims to evaluate the effects of finerenone on composite kidney and CV endpoints in varying stages of CKD (defined by estimated glomerular filtration rate [eGFR] and urine albumin-to-creatinine ratio [UACR]). The benefits of combining finerenone with SGLT-2is was also evaluated.spa
dc.description.filiationUEMspa
dc.description.impact6.0 Q1 JCR 2022spa
dc.description.impact1.173 Q1 SJR 2022spa
dc.description.impactNo data IDR 2022spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationRossing, P., Agarwal, R., Anker, S. D., Filippatos, G., Pitt, B., Ruilope, L. M., Joseph, A., Gebel, M., Kolkhof, P., Nowack, C., & Bakris, G. L. (2022). POS-350. Finerenone in mild to severe chronic kidney disease and type 2 diabetes: The fidelity prespecified pooled analysis. Kidney International Reports, 7(2), S157-S158. https://doi.org/10.1016/j.ekir.2022.01.371spa
dc.identifier.doi10.1016/j.ekir.2022.01.371
dc.identifier.issn2468-0249
dc.identifier.urihttp://hdl.handle.net/11268/11184
dc.language.isoengspa
dc.peerreviewedSispa
dc.rights.accessRightsrestricted accessspa
dc.subject.otherDiabetes mellitus tipo 2spa
dc.subject.otherFallo renal crónicospa
dc.subject.unescoEnfermedad cardiovascularspa
dc.subject.unescoSistema endocrinospa
dc.subject.unescoTratamiento médicospa
dc.titlePOS-350. Finerenone in mild to severe chronic kidney disease and type 2 diabetes: The fidelity prespecified pooled analysisspa
dc.typeconference outputspa
dspace.entity.typePublication

Files

Collections

Otras Áreas de Actividad Física y Deporte